How does this Pharmaceutical major hold up against its peers?
You don't need me to tell you how the banking crash and recession have pushed many companies to the brink of bankruptcy. Shares such as the Barclays (LSE: BARC), Nokia (NYSE: NOK.US) and Home Retail Group (LSE: HOME) have collapsed 80% or more since the credit crunch erupted. With the future in Europe and the banking sector still far from certain, many more companies could be at risk of going the same way.
Like you no doubt, I'm always keen to ensure my potential investments aren't just about to go bust! Indeed, I'm convinced avoiding losers is just as important as picking winners in today's choppy market.
With all that in mind, I use something called a Z-Score to help me sidestep portfolio disasters. This Z-Score was developed in the 1960s and evaluates various financial ratios to provide an overall verdict on a company's strength. Effectively the higher the number the less likely the company is to go bust, although of course this is best taken in context of the Z-Score of its industry as a whole. Generally speaking, a score above 3 suggests the company is in very good health, while a score below 1.8 indicates the possibility of the firm going under. The Z-Score is not perfect of course, and I would encourage, if you are interested, to read more details.
Today I'm assessing GlaxoSmithKline (LSE: GSK). Here are my Z-Score calculations:
Working Capital/Total Assets
Retained Earnings/Total Assets
Market Value of Equity/Total Liabilities
This comparison looked at the full-year results for Glaxo ending December 31, 2011, and compares the figures with the same reports for a number of rival firms, including AstraZeneca (LSE: AZN) and Shire (NYSE: SHRS.US).
The results show that Glaxo's Z-Score came in almost 20% lower than the sector average, due in main to a comparatively high level of total liabilities. This saw the market value to liabilities ratio also far below the sector, despite the company’s market value of equity itself actually coming in-line with that of its competitors.
Between 2010 and 2011 Glaxo's Z-Score increased by 18% from 2.38, while the sector average increased by just 13%. This gain mainly derived from the EBIT to Total Assets ratio, which more than doubled through the period following a sharp rise in operating profit, as well as the liquidating of some assets for the company.
Glaxo's weakest comparative area is that of retained earnings to total assets, where despite fairly similar levels of assets to its equally-sized peers, a very low level of retained earnings for the firm has this ratio less than half of the sector.
Significantly, both working capital and retained earnings for Glaxo dropped by relatively large amounts between 2010 and 2011, and although the retained earnings to total assets ratio fell 27% in the period (compared to a 21% increase for the sector), the move in retained earnings to total assets actually came in-line with a similar decline for the industry.
So we have a mixed picture then. At 2.82, Glaxo's Z-Score is still well into 'strong' territory, although not to the levels of the industry as a whole, which could be worrying. Certainly falling working capital and comparatively low retained earnings could be a problem in an industry where investment and development of new drugs are vital.
However, whilst there may be better pharmaceutical companies to buy if you are looking for an investment, GlaxoSmithKline isn't going to go bust any time soon.
Share ideas from a proven recession-beater
Finally, if you are looking for share ideas from somebody who has avoided the worst of the recession, you must read this special free report about Neil Woodford.
You see, Mr Woodford runs portfolios that total a staggering £20 billion and famously sold out of banking shares well before the credit crunch. Right now, he's focusing on a small collection of defensive, dividend-paying shares, the full details of which can be found in "8 Income Shares Held By Britain's Super Investor".
By closely studying accounts for problems, Mr Woodford has seen his blue-chip portfolios soar up to 347% during the fifteen years to 2011.
If you, like Mr Woodford, are concerned about today's global economy, I urge you to download this Neil Woodford report while it is still free and available.
Are you looking to profit from this uncertain economy? "10 Steps To Making A Million In The Market" is the very latest Motley Fool guide to help Britain invest. Better. We urge you to read the report today -- it's free.
Further Motley Fool investment opportunities:
> Karl does not own any of the shares mentioned in this article.